Wednesday, July 8, 2026

biotech · Post Traumatic Stress Disorder · Prosthetic Joint Infection · ADPT

Adaptive Biotechnologies

Adaptive Biotechnologies clinical programs — 19 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1165 Eastlake Ave E, Seattle, Washington 98109, US HQ
2009 Founded
659 Employees
Public company Type
ADPT · NYSE Ticker
Company details
Status
Public
HQ
1165 Eastlake Ave E, Seattle, Washington 98109, US
Founded
2009
Employees
659
Programs
19
Drugs
23
Patents
12
Intelligence · Clinical Programs

Adaptive Biotechnologies projects

19 ClinicalTrials.gov programs sponsored by Adaptive Biotechnologies.

Adaptive Biotechnologies has 19 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Ceftriaxone

    Adaptive Biotechnologies Corp

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial
  2. GCAR-7213

    Adaptive Biotechnologies Corp

    Oncology - Glioblastoma (GBM)

    phase 3 small molecule active

    1 trial
  3. Temozolomide

    Adaptive Biotechnologies Corp

    Glioblastoma

    phase 3 small molecule active

    1 trial
  4. Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset

    Adaptive Biotechnologies Corp

    Chronic Tonal Tinnitus

    phase 2 other completed

    1 trial
  5. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial
  6. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial
  7. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Osteomyelitis

    phase 2 mab terminated

    1 trial
  8. Bendamustine

    Adaptive Biotechnologies Corp

    Lymphoma

    phase 2 small molecule active

    1 trial
  9. Intervention A Fluoxetine Hydrochloride (HCl)

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    2 trials
  10. Intervention B Vilazodone Hydrochloride (HCl)

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial
  11. Intervention C Daridorexant

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial
  12. Intervention D SLS-002

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule on hold

    1 trial
  13. Mosunetuzumab

    Adaptive Biotechnologies Corp

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial
  14. Nivolumab

    Adaptive Biotechnologies Corp

    Bladder Cancer

    phase 2 small molecule completed

    1 trial
  15. Obinutuzumab

    Adaptive Biotechnologies Corp

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial
  16. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials
  17. Venetoclax monotherapy

    Adaptive Biotechnologies Corp

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial
  18. ANM T30 CR®-System

    Adaptive Biotechnologies Corp

    Tinnitus

    approved other completed

    1 trial
  19. Radiation

    Adaptive Biotechnologies Corp

    Rectal Cancer

    other completed

    1 trial

Frequently asked questions

How many clinical projects does Adaptive Biotechnologies have?

19 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.